Clinical Trial Update: Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating pazopanib monotherapy as a second-line treatment after first-line chemotherapy in ovarian, fallopian tube, or primary peritoneal cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Pazopanib (Pazopanib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Ovarian Cancer | Phase 3 | Status: COMPLETED | Results posted: 2013-12-19